PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE)
Pharmacology, Toxicology and Pharmaceutical Science
6
4%
Nursing and Health Professions
3
2%
Other
13
10%
Unknown
32
24%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 August 2014.
All research outputs
#9,303,935
of 31,439,095 outputs
Outputs from Retina
#639
of 4,453 outputs
Outputs of similar age
#73,958
of 283,250 outputs
Outputs of similar age from Retina
#6
of 30 outputs
Altmetric has tracked 31,439,095 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 4,453 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 283,250 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.
